286 related articles for article (PubMed ID: 24652518)
1. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
Hagstrom SA; Ying GS; Pauer GJ; Sturgill-Short GM; Huang J; Maguire MG; Martin DF;
JAMA Ophthalmol; 2014 May; 132(5):521-7. PubMed ID: 24652518
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
[TBL] [Abstract][Full Text] [Related]
3. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
[TBL] [Abstract][Full Text] [Related]
6. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
7. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
[TBL] [Abstract][Full Text] [Related]
9. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
[TBL] [Abstract][Full Text] [Related]
10. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.
Davis J; Olsen TW; Stewart M; Sternberg P
Am J Ophthalmol; 2011 Oct; 152(4):509-14. PubMed ID: 21961847
[TBL] [Abstract][Full Text] [Related]
11. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Maguire MG; Ying GS; Jaffe GJ; Toth CA; Daniel E; Grunwald J; Martin DF; Hagstrom SA;
JAMA Ophthalmol; 2016 Jun; 134(6):674-81. PubMed ID: 27099955
[TBL] [Abstract][Full Text] [Related]
12. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
Scoles D; Ying GS; Pan W; Hua P; Grunwald JE; Daniel E; Jaffe GJ; Toth CA; Martin DF; Maguire MG;
JAMA Ophthalmol; 2020 Mar; 138(3):276-284. PubMed ID: 31999297
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
Shin JY; Woo SJ; Ahn J; Park KH
Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928
[TBL] [Abstract][Full Text] [Related]
15. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
[TBL] [Abstract][Full Text] [Related]
16. Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Gewaily DY; Grunwald JE; Pistilli M; Ying GS; Maguire MG; Daniel E; Ostroff CP; Fine SL;
Am J Ophthalmol; 2014 Sep; 158(3):525-31.e2. PubMed ID: 24949820
[TBL] [Abstract][Full Text] [Related]
17. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
Maguire MG; Daniel E; Shah AR; Grunwald JE; Hagstrom SA; Avery RL; Huang J; Martin RW; Roth DB; Castellarin AA; Bakri SJ; Fine SL; Martin DF;
Ophthalmology; 2013 Oct; 120(10):2035-41. PubMed ID: 23706946
[TBL] [Abstract][Full Text] [Related]
18. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
Kang HK; Yoon MH; Lee DH; Chin HS
Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
[TBL] [Abstract][Full Text] [Related]
20. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
